TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00608231

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine Hydrochloride Infusion
Description: Dexmedetomidine Hydrochloride Infusion(0.5-1.0 mg/kg)intravenous over 10 minutes with dose adjustment for goal Richmond Agitation and Sedation Scale of -1 During deep brain stimulator implantation surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine Hydrochloride Infusion
Description: Dexmedetomidine Hydrochloride Infusion(0.5-1.0 mg/kg)intravenous over 10 minutes with dose adjustment for goal Richmond Agitation and Sedation Scale of -1 During deep brain stimulator implantation surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine Hydrochloride Infusion
Description: Dexmedetomidine Hydrochloride Infusion(0.5-1.0 mg/kg)intravenous over 10 minutes with dose adjustment for goal Richmond Agitation and Sedation Scale of -1 During deep brain stimulator implantation surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine Hydrochloride Infusion
Description: Dexmedetomidine Hydrochloride Infusion(0.5-1.0 mg/kg)intravenous over 10 minutes with dose adjustment for goal Richmond Agitation and Sedation Scale of -1 During deep brain stimulator implantation surgery

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Normal Saline intravenous over 10 minutes during deep brain stimulator implantation surgery

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Normal Saline intravenous over 10 minutes during deep brain stimulator implantation surgery

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Normal Saline intravenous over 10 minutes during deep brain stimulator implantation surgery

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Normal Saline intravenous over 10 minutes during deep brain stimulator implantation surgery
Study: NCT01901237

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Hatha Yoga
Description: This is a 7-week home/hospice-based instructive Hatha yoga program (available on DVD) for adolescent and young adults diagnosed with a non-curative cancer. Participants will be asked to complete a minimum of one, 75-minute yoga session per week. The DVD package includes four discs that increase in difficulty over the course of the 7-week program. The DVD focuses on postures and breathing exercises. Participants will be asked to keep track of the number and duration of yoga sessions completed over the 7-week period.
Study: NCT01974245

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cholecalciferol
Description: 100,000 IU/week for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 100 drops/ week for 12 weeks
Study: NCT00779467

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neostigmine
Description: utilizing 3 different dosages of neostigmine and comparing it to the standard of fentanyl. Infusion runs via PCA throughout labor analgesia.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neostigmine
Description: utilizing 3 different dosages of neostigmine and comparing it to the standard of fentanyl. Infusion runs via PCA throughout labor analgesia.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neostigmine
Description: utilizing 3 different dosages of neostigmine and comparing it to the standard of fentanyl. Infusion runs via PCA throughout labor analgesia.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fentanyl
Description: fentanyl 2 mcg/ml
Study: NCT01113281

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VPM1002 live vaccine

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: commercially available live vaccine BCG
Study: NCT03247855

Intervention type: PROCEDURE
Group type: OTHER
Intervention: minimal invasive coronary artery bypass graft surgery
Description: coronary artery bypass grafting surgery by using a minimal invasive technique
Study: NCT02442869

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stage 1 Treatment as usual (TAU)
Description: 4-8 weeks of the treatment typically provided by that counselor with the caveat that neither DBT nor CAMS can be provided.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stage 1 Treatment as usual (TAU)
Description: 4-8 weeks of the treatment typically provided by that counselor with the caveat that neither DBT nor CAMS can be provided.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stage 1 CAMS
Description: 4-8 weeks of Collaborative Assessment and Management of Suicidality (CAMS)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stage 1 CAMS
Description: 4-8 weeks of Collaborative Assessment and Management of Suicidality (CAMS)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stage 2 CAMS
Description: 4-16 weeks of Collaborative Assessment and Management of Suicidality (CAMS)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stage 2 CAMS
Description: 4-16 weeks of Collaborative Assessment and Management of Suicidality (CAMS)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stage 2 Dialectical Behavioral Therapy (DBT)
Description: 4-16 weeks of Dialectical Behavioral Therapy (DBT)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stage 2 Dialectical Behavioral Therapy (DBT)
Description: 4-16 weeks of Dialectical Behavioral Therapy (DBT)
Study: NCT02789709

Intervention type: PROCEDURE
Intervention: Surgery
Description: Segmental resection for colon cancer and anterior resection in patients with rectal cancer
Study: NCT00004196

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: recombinant interferon alfa

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: recombinant interferon alfa

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: recombinant interferon alfa

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: lymphangiography

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: lymphangiography

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Observation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Observation
Study: NCT02353598

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crenezumab dose level 1
Description: Participants will receive crenezumb dose level 1 IV infusion once every 4 weeks up to Week 13 in double-blind treatment window or up to Week 61 in optional OLE window.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crenezumab dose level 1
Description: Participants will receive crenezumb dose level 1 IV infusion once every 4 weeks up to Week 13 in double-blind treatment window or up to Week 61 in optional OLE window.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crenezumab dose level 2
Description: Participants will receive crenezumb dose level 2 IV infusion once every 4 weeks up to Week 13 in double-blind treatment window or up to Week 61 in optional OLE window.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crenezumab dose level 2
Description: Participants will receive crenezumb dose level 2 IV infusion once every 4 weeks up to Week 13 in double-blind treatment window or up to Week 61 in optional OLE window.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crenezumb dose level 3
Description: Participants will receive crenezumb dose level 3 IV infusion once every 4 weeks upto Week 13 in double-blind treatment window or up to Week 61 in optional OLE window.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crenezumb dose level 3
Description: Participants will receive crenezumb dose level 3 IV infusion once every 4 weeks upto Week 13 in double-blind treatment window or up to Week 61 in optional OLE window.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive placebo matched to crenezumab IV infusion once every 4 weeks upto Week 13 in double-blind treatment window.
Study: NCT03157258

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Network Training
Description: Members of HIV+ social networks randomized to this arm will be trained to endorse compliance with medical guidelines and adherence to medical treatment regimens to their friends.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Single Care-Related Counseling Session and Referral to Care
Description: Members of HIV+ social networks randomized to this arm will attend a single, brief care-related counseling session and referral to care at baseline.
Study: NCT01988792

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Human milk fortifiers

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Human milk fortifiers
Study: NCT03421392

Intervention type: OTHER
Intervention: non interventional study
Description: non interventional study

Intervention type: OTHER
Intervention: non interventional study
Description: non interventional study

Intervention type: OTHER
Intervention: non interventional study
Description: non interventional study
Study: NCT04282993

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wearable devices for identifying and measuring risk factors for ischemic stroke
Description: Identifying and monitoring cerebrovascular risk factors using wearable devices

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care monitoring
Description: Periodical medical examinations
Study: NCT00676351

Intervention type: PROCEDURE
Group type: OTHER
Intervention: body plethysmography
Description: Same tests were performed at 18 and 24 months. At 30 and 36 months, pulmonary function was evaluated by measuring respiratory resistances using an oscillometry system and an occlusion system
Study: NCT01572454

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine infusion
Description: Dexmedetomidine infusion 0.2 mcg/kg/hr during anesthetic induction 0.3 - 0.7 mcg/kg/hr during the surgery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil infusion
Description: Remifentanil infusion 0.05 - 0.3 mcg/kg/min during the anesthetic induction and surgery
Study: NCT01870960

Intervention type: OTHER
Group type: OTHER
Intervention: 7 patients will be recuting to received EMDOGAIM in left side

Intervention type: OTHER
Group type: OTHER
Intervention: 7 patients will be recuting to received EMDOGAIM in right side
Study: NCT01654367

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic Acid and Aromatase Inhibitors
Description: Zoledronic Acid and Aromatase Inhibitors as Adjuvant Therapy
Study: NCT00456521

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone SR 32 mg/ bupropion SR 360 mg/ day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive group lifestyle modification counseling

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Intensive group lifestyle modification counseling
Study: NCT04276597

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 177Lu-DOTATOC
Description: 177Lu labeled somatostatin receptors targeting ligand
Study: NCT02095587

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IPI-145
Description: 25 mg single oral capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IPI-145
Description: 25 mg single oral capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IPI-145
Description: 25 mg single oral capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IPI-145
Description: 25 mg single oral capsule
Study: NCT01773382

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: weight reduction
Description: 1. Set target daily energy requirement by nutritionist (25-30 Kcal/Kg/day minus 500 Kcal)~2. Advice and encourage patients to do aerobic exercise at least 30 minutes/day for 4-5 days/weeks.~3. Daily body weight measurement.~4. Record food diary
Study: NCT03140384

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Assess the efficacy and side effects of Misoprostol according to the route of administration
Description: Assess the efficacy and side effects of Misoprostol according to the route of administration

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Assess the efficacy and side effects of Misoprostol according to the route of administration
Description: Assess the efficacy and side effects of Misoprostol according to the route of administration

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Assess the efficacy and side effects of Misoprostol according to the route of administration
Description: Assess the efficacy and side effects of Misoprostol according to the route of administration
Study: NCT06119360

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Face-to-face approach
Description: A front-facing approach and insert the lightwand following the patient's tongue base curvature without scooping movement

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Conventional approach
Description: Patients were positioned supine and the intubator stood above the patient's head. Opening the mouth and slightly pulling the mandible with one hand, the intubator inserted the lightwand-tracheal tube assembly at midline into the patient's mouth under the ambient light being turned off. To identify the location of the lighted tip, the intubator could move the lightwand back and forth gently, Once the red light of the tip was located at the midline of the patient's neck, the pre-launched tube was inserted smoothly into the patient's airway unless there was no resistance
Study: NCT01260285

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vardenafil
Description: 10 mg PO once
Study: NCT05004753

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Artemisinin
Description: a herbal supplement

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: corticosteroids
Study: NCT06182189

Intervention type: OTHER
Intervention: Observation of patients with a benign prostatic hyperplasia condition
Description: Observation of patients with a benign prostatic hyperplasia condition who have undergone surgery
Study: NCT00740844

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intermittent pneumatic compression of the lower limbs
Description: Intermittent pneumatic compression of the lower limbs during hospitalisation in reanimation unit
Study: NCT01810354

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cefazolin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefazolin
Study: NCT01113801

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2382770
Description: Subcutaneous injection given monthly for 12 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2382770
Description: Subcutaneous injection given monthly for 12 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2382770
Description: Subcutaneous injection given monthly for 12 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneous injection given monthly for 12 months
Study: NCT04333823

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 5mg
Description: Dapagliflozin tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sugar pill manufactured to mimic Dapagliflozin 5mg tablet
Study: NCT03080311

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APG-1252
Description: Multiple dose cohorts, 30 minute IV infusion, twice weekly for 3 weeks of a cycle with 28 days.
Study: NCT01354951

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prostate Biopsy, Focal Brachytherapy , Assessment of QOL
Description: A re-staging transrectal or transperineal ultrasound-guided prostate biopsy as currently performed at participating institutions. Focal brachytherapy will be performed at 8 weeks following the transrectal or transperineal biopsy or sooner if the patient has recovered from the repeat biopsy and the treating physician determines it is safe to proceed with treatment. The regions will be targeted with the prescription dose and receive 144 Gy of Iodine-125 (I-125). The quality-of-life assessment will focus on erectile function, urinary function, bowel function, and general health related quality of life. The patients will complete this assessment at baseline and then approximately 3 ± 1 months, 6 ± 1 months, 12 ± 2 months, 18 ± 2 months, and 24 ± 2 months after treatment.
Study: NCT01949051

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levocabastine
Description: Intranasal aqueous 50 mcg microsuspension of levocabastine supplied in an amber glass bottle fitted with a white top actuated plastic metering atomising spray pump filled with a uniform white suspension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Intranasal aqueous 0 mcg microsuspension supplied in an amber glass bottle fitted with a white top actuated plastic metering atomising spray pump filled with a uniform white suspension
Study: NCT01550640

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: bolus of remifentanil 1 µg/kg will be given 30 sec before induction to general anesthesia
Study: NCT00492661

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus With Diet and Exercise Intervention
Description: Participants on tacrolimus for immunosuppression will be provided with intensive dietary advice and supervised for a period of 6 months. Dosage and administration of tacrolimus will be as per Investigator's discretion.
Study: NCT03595033

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iPad app-based intervention
Description: The 1-hour of home based intervention will break into three 20-min sessions, each including iPad apps targeting one of the three domains of deficits: visual attention, visual-spatial reasoning, and visual-motor skills.
Study: NCT00109889

Intervention type: PROCEDURE
Group type: OTHER
Intervention: magnetic resonance imaging
Description: magnetic resonance imaging (MRI)

Intervention type: PROCEDURE
Group type: OTHER
Intervention: positron emission tomography
Description: positron emission tomography (PET)
Study: NCT02736409

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Budesonide Suspension (OBS)
Description: OBS 2mg twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Budesonide Suspension (OBS)
Description: OBS 2mg twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Budesonide Suspension (OBS)
Description: OBS 2mg twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo dose
Study: NCT00774319

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: conventional radiotherapy with 'high' dose cisplatin
Description: radiotherapy: 5 fractions/week, total treatment time 7 weeks. Dose to gross tumor volume 70 Gy/35 fractions, dose to elective nodal areas 46 Gy/23 fractions.~100 mg/m2 cisplatin iv on day 1, 22 and 43

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: accelerated radiotherapy with 'low' dose cisplatin
Description: Accelerated radiotherapy 6 fractions/week, total treatment time 6 weeks. During one of the weekdays two fractions will be delivered with an interval of at least 6h. Dose to gross tumor volume 70 Gy/35 fractions, dose to elective nodal areas 46 Gy/23 fractions cisplatin 40 mg/m2 iv on day 1,8,18,22,29,35
Study: NCT00449540

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active Transcranial Magnetic Stimulation (TMS) Device
Description: Transcranial Magnetic Stimulation Device treatment

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham TMS Device
Description: Simulated Sham treatment without TMS delivery
Study: NCT03055351

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stop&Go Intervention
Description: Stop\&Go intervention will be based on Self-determination theory. Patients will participate in four practically-oriented training sessions, focused on (1) nutrition and oral hygiene, (2) sleep habits and self-care, (3) physical activity and exercise, and (4) smoking cessation. In addition, the entire inpatient detoxification centre will be adapted to encourage autonomous physical activity and to reinforce the ideas presented in the training sessions.
Study: NCT04539847

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High-end hearing aid
Description: hearing aid with premium level of technology

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Basic hearing aid
Description: hearing aid with basic level of technology
Study: NCT01366560

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Active
Description: GSK962040 125mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo
Study: NCT04542655

Intervention type: OTHER
Group type: OTHER
Intervention: Ergometer Cycling followed by treadmill running
Description: The participants undergo ergometer cycling, treadmill running and rest.

Intervention type: OTHER
Group type: OTHER
Intervention: Treadmill Running followed by ergometer cycling
Description: The participants undergo treadmill running, ergometer cycling and rest.

Intervention type: OTHER
Group type: OTHER
Intervention: Rest
Description: The participants undergo ergometer cycling, treadmill running and rest.

Intervention type: OTHER
Group type: OTHER
Intervention: Rest
Description: The participants undergo ergometer cycling, treadmill running and rest.
Study: NCT00759954

Intervention type: DRUG
Group type: OTHER
Intervention: morphine sulfate sustained-release capsules
Description: 1 x 200 mg, single-dose capsule

Intervention type: DRUG
Group type: OTHER
Intervention: morphine sulfate sustained-release capsules
Description: 1 x 200 mg, single-dose capsule